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co-occurrence of symptoms of Attention Deﬁ cit Hyperactivity Disorder (ADHD), a
neurobehavioral condition that impairs organization and executive planning that
affects between 1–6% of adults in the United States. METHODS: The study design 
utilized an internet-based panel of 567 T2DM cases that consented to participate in 
a survey. In addition to de-identiﬁ ed demographic data, respondents were asked to
provide information on diabetes self-care, HbA1c values, ADHD symptoms, and 
health care resource utilization. RESULTS: The results indicated that those respon-
dents who had symptoms of ADHD had more ofﬁ ce visits for diabetes-related issues 
(p  .0002), more ofﬁ ce visits for illness or injury (p  .0007), and more hospitaliza-
tions for illness or injury (p  .0493) compared with T2DM respondents without
symptoms of ADHD. For those who reported HbA1c values, regression tree analyses
suggested low diabetes self-care scores and high ADHD symptom scores were associ-
ated with worse HbA1c values. CONCLUSIONS: These ﬁ ndings suggest that the co-
occurrence of T2DM and ADHD symptoms could result in poor HbA1c management
and may lead to increased resource utilization.
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THE VALIDATION OF TURKISH VERSION OF PERSONAL AND SOCIAL 
PERFORMANCE SCALE (PSP)
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OBJECTIVES: Functioning in severe mental disorders is very important and brief 
rating instruments are needed. Personal and Social Performance Scale (PSP) is one of 
the instruments which can be used in severe mental disorders in a short time.
METHODS: The study was performed in the psychiatry departments of two university 
hospitals. In- or outpatients diagnosed as schizophrenia or bipolar disorder were
included in the study. Exclusion criteria were comorbidity of other psychiatric disorders
(including substance use disorders) and physical diseases. For concurrent validity,
besides PSP, Clinical Global Impression (CGI), Global Assessment of Functioning
(GAF) of DSM-IV, Quality of Life and Satisfaction Questionnaire (QLS-Q), and Posi-
tive and Negative Schizophrenia Scale (PANSS) were used. For discriminant validity,
the mean scores of PSP of patients with and without symptomatic remission were
compared. RESULTS: The study was carried out with a total of 135 patients, 105
(77.8%) diagnosed as schizophrenia and 30 (22.2%) diagnosed as bipolar disorder. 
The mean age of the patients was 34.1 o 10.7 and 75 (55.6%) of them were male. The
duration of illness was 10.4 o 7.5 years. The mean score of PSP was 60.0 o 17.1. In
the reliability analysis, the Cronbach alpha coefﬁ cient was 0.8327, and item-total score
correlations were between 0.4920–0.7462. In the validity analyses, the total score of 
PSP was signiﬁ cantly correlated with the total score of CGI (r  0.854, p  0.0001), 
GAF (r  0.748, p  0.0001), QLS-Q (r  0.734, p  0.0001), and PANSS (r  0.664, 
p  0.0001). The difference between the patients with and without symptomatic remis-
sion was signiﬁ cant (54.8 o 14.8 vs. 72.6 o 9.8, t  7.434, p  0.0001). CONCLU-
SIONS: The Turkish version of PSP was found to be reliable and valid in severe mental
disorders. It can be used both in clinical trials and routine follow-up.
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OBJECTIVES: The Life Participation Scale for Children was designed to measure
treatment-related improvements in adaptive functioning in children with ADHD. To
measure these attributes in adult subjects, we developed a Life Participation Scale for 
Adults (LPS-A). METHODS: LPS-A items were selected by convening focus groups, 
interviewing experts, and performing structured cognitive interviews to improve item
wording. These were administered in a 2-week study of treated (N  10) and untreated 
(N  10) participants with ADHD and normal controls (N  11). Cronbach’s alpha,
Lin’s concordance correlation, and Pearson’s correlations were used to assess internal
consistency, test-retest reliability, and convergent/divergent validity. LPS-A scores were
compared for ADHD/control, treated/untreated, and less/more severe participants to 
measure discriminant validity. RESULTS: The LPS-A demonstrated internal consis-
tency (Cronbach’s alpha  0.92–0.96). Concordance correlations indicated test-retest 
reliability (r  0.79 to 0.86). Convergent, divergent, and discriminant validity were 
demonstrated. CONCLUSIONS: The initial examination of the LPS-A suggests accept-
able levels of validity and reliability. Larger studies will provide further information 
about the psychometric properties of the LPS-A. The LPS-A appears to be a promising 
new instrument for measuring adaptive function in adults with ADHD.
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EVALUATING CENTRAL NERVOUS SYSTEM DRUG LABELS FOR
PATIENT-REPORTED OUTCOMES CLAIMS
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OBJECTIVES: Previous studies (prior to 2003) have suggested that central nervous 
system (CNS) drugs have had the highest number of patient-reported outcomes (PRO)
claims used in product approvals. This study examined the use of PRO as efﬁ cacy 
endpoints in label claims of recent FDA-approved CNS drugs between 2003 and 2008. 
METHODS: Product labels of FDA-approved prescription-only New Molecular Enti-
ties (NMEs) from the CNS drug category between January 2003 and October 2008 
were reviewed. The most recent product label, obtained either from the FDA’s Center
for Drug Evaluation and Research (CDER) or directly from the company website, was 
used for all the drugs, including the drugs withdrawn from the market. Efﬁ cacy end-
point data was obtained from the Clinical Studies section of the approved product 
label. Efﬁ cacy measures were categorized into PRO, clinician-reported outcomes
(CRO) and laboratory devices. RESULTS: During the ﬁ ve year period, 14 of the 153
FDA-approved NMEs were CNS agents. The CNS agents included four drugs for 
neuromuscular disorders, two antipsychotics, two antidepressants, two sedatives, one
smoking cessation drug, one analgesic, one CNS stimulant, and one drug treating 
alcoholism. Of the 28 efﬁ cacy measures used in the CNS product labels, seven (25%) 
were PRO. The four drugs using PRO endpoints included one antidepressant, one
analgesic, one CNS stimulant and one smoking cessation drug. Of the seven PRO 
used, three were symptom scales, two were global impression scales, one scale mea-
sured condition-speciﬁ c health-related quality-of-life, and one scale measured func-
tional impairment. The percentage of approved CNS drugs using PRO as efﬁ cacy
endpoints in label claims declined since 2002 (2003–08: 28.5%; 1997–2002: 75%). 
CONCLUSIONS: The latter half of the past decade has seen a considerable decrease 
in the number of CNS drugs that have had PRO-based label claims. Symptoms scales 
are the prominent type of PRO used in CNS drug label claims.
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OBJECTIVES: To identify the clinical outcomes associated with self-perceived copay 
burden among patients with schizophrenia. METHODS: Data were taken from a 
nationwide survey of adults (age 18) with a self-reported diagnosis of schizophrenia.
The survey was ﬁ elded from December 2007 to February 2008. Data were collected 
through both self-reported questionnaires administered on-site, and via the Internet.
Inclusion criteria for analysis were no exposure to clozapine, no use of a depot injec-
tion of an antipsychotic, and currently using a second generation antipsychotic (SGA). 
Outcomes included emergency room (ER) visits, hospitalization, suicide attempt, 
missed work (among employed patients), as well as experiencing severe distress deﬁ ned 
as a score of 0–60 on the Psychological General Well Being (PGWB) scale. Assessment
of the effects of self-perceived copay burden on outcomes was calculated using logistic
regression models. Demographics, substance use, concomitant psychotropic medica-
tions, comorbidity, and health insurance were controlled for in the models. RESULTS:
Of the patients who met the inclusion criteria (n  351), 39% (n  137) self-reported 
experiencing copay burden. Adjusting for covariates, patients who experienced copay
burden were more likely to use the ER [OR  2.157; 95% CI:(1.322, 3.520); p 
0.002], have a hospitalization [OR  2.512; 95% CI: (1.475, 4.277); p  0.001], have 
a suicide attempt [OR  2.385; 95% CI: (1.156, 4.920); p  0.019], and experience
severe psychological distress [OR  1.833; 95% CI: (1.092, 3.075); p  0.022]. Among 
the 110 patients who were employed, those who experienced copay burden were more 
likely to have missed work in the past month [OR  7.193; 95% CI: (2.554, 20.256);
p  0.001]. CONCLUSIONS: Among patients with schizophrenia using SGAs, greater 
copay burden was associated with increased ER visits, hospitalization, suicide 
attempts, missed work, and psychological distress. Patient’s health care use and psy-
chological well being are likely to beneﬁ t from less restrictive formularies that reduce 
copay burden for antipsychotic medication.
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PATIENT-REPORTED HEALTH STATUS IN CHRONIC MEDICAL DISORDER
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OBJECTIVES: Our objective was to examine the association of health status measures
with depression diagnosis in chronic medical disorder (CMD) patients. METHODS:
For the retrospective analysis, we extracted data on / 18 year-old employed adults 
from the pooled 2004–5 Medical Expenditure Panel Survey. Data included ICD-9-
CM-coded CMD (hyperlipidemia, heart-disease, arthritis/other joint-disorders, 
chronic obstructive pulmonary disease, hypertension, or diabetes), depression, age,
gender, race, poverty-level, health-insurance, urban-residence, and any depression 
treatment (psychotherapy or antidepressant) and patient-reported health-status mea-
sures (physical component summary, PCS, and mental component summary, MCS 
scores from the Short-Form 12 (SF-12); patient health questionnaire, PHQ-2; and 
Kessler Index, K6) on a continuous scale. We compared mean and standard deviation 
of health status measures in CMD patients with and without depression using t-tests. 
We weighted sample estimates and calculated 95 percent conﬁ dence limits (CL) using 
the Taylor expansion method. In multivariate logistic regression analyses, after con-
trolling for other characteristics, we examined the association of health status mea-
sures with depression diagnosis. RESULTS: Health status signiﬁ cantly differed in
CMD patients with and without depression (n  9,738, Means; SF-12 PCS 48.25 vs.
50, SF-12 MCS 43.76 vs. 52.03, PHQ-2 1.59 vs. 0.53, and K6 6.3 vs. 2.9, all 
p  0.001). Increasing scores on the SF-12 PCS and SF-12 MCS decreased the odds 
of depression while increasing scores on the PHQ-2 and K6 increased the odds of 
depression. In a multivariate model, after adjusting for covariates, the SF-12 MCS (a 
one-unit increase resulted in 0.97 times the risk for depression, 95%CL: 0.95–0.99, 
p  0.0009) and the PHQ-2 (a one-unit increase results in 1.2 times the risk for 
depression, 95%CL: 1.07–1.35, p  0.0022) were signiﬁ cantly associated with depres-
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sion diagnosis, while SF-12 PCS and K6 were not associated (p  0.05). CONCLU-
SIONS: Routinely collected patient reported health status may be useful to providers 
and payers as an aid in diagnosing depression in CMD patients.
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DIFFICULT TO SWALLOW: PATIENT PREFERENCES REGARDING
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Bhosle MJ1, Benner JS1, DeKoven M1, Shelton J2
1IMS Health, Falls Church, VA, USA, 2Answers & Insights Market Research, Inc, Indianapolis, IN, 
USA
OBJECTIVES: Characteristics such as tablet size and ease-of-swallowing can affect
patients’ treatment preference, and could in turn affect patient medication compliance.
The objectives of this research were to determine the degree to which swallowing 
Valproate (VP) tablets is an issue, and the predictors of patient preference. METHODS:
We conducted a quantitative telephone survey of adults (n  400, q18 years old) who 
currently take (n  236) or previously took (n  164) VP tablets within the past 6 
months (125 mg, 250 mg, or 500 mg). After online recruitment and screening, eligible
participants completed a structured interview about medication use, perceived tablet
characteristics, and preferences. Multivariate regression analyses were conducted to
determine predictors of treatment preference. RESULTS: Respondents took an average 
2.5 (SD  1.23) VP tablets/day primarily to treat bipolar disorder (65.0%, n  260),
migraine (12.5%, n  50), or epilepsy (11.7%, n  47). More than half of the patients 
indicated that VP tablets were ‘uncomfortable to swallow’ (68.5%, n  274) and were 
‘very interested’ (65.8%, n  263) in medications that were easier to swallow. When 
choosing conceptually between taking their VP tablet once/day or an equally safe and 
effective but signiﬁ cantly smaller soft gel capsule twice/day, the majority (82.8%, n 
331) preferred the soft gel capsule. In the multivariate regression analysis, perceiving 
soft gel capsules to be easier to swallow (OR  73.54; 95% CI  15.01–360.40) and 
taking VP more frequently (OR  2.02; 95% CI  1.13–3.61) were signiﬁ cant predic-
tors of soft gel capsule treatment preference. CONCLUSIONS: In this survey-based 
study, users of VP would prefer a formulation that is easier to swallow. A higher 
patient preference may improve medication compliance. When choosing between 
medications with similar efﬁ cacy and safety, physicians can consider patient prefer-
ences for speciﬁ c tablet characteristics to optimize conditions for medication compli-
ance. Further research is warranted to examine compliance with medications that are 
easier to swallow.
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MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENIA 
TREATED WITH PALIPERIDONE ER AFTER SUBOPTIMAL RESPONSE TO 
ORAL RISPERIDONE
Canuso CM1, Grinspan A1, Merriman UE1, Damaraju C1, Dirani RG1, Kalali A2, Alphs L1
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OBJECTIVES: Medication satisfaction in subjects with schizophrenia may be related
to efﬁ cacy and long-term adherence. This study evaluated medication satisfaction after
treatment with paliperidone ER in subjects with a current suboptimal response to oral 
risperidone. METHODS: A 6-week, prospective, international, randomized, blinded-
initiation study. Inclusion criteria: schizophrenia per DSM-IV, treated with oral ris-
peridone (4 or 6 mg/day) at least 4 weeks prior to entry, PANSS score q4 on q3 items 
(tension, unusual thought content, delusions, hallucinatory behavior, excitement, gran-
diosity or suspiciousness/persecution) and dissatisfaction with current medication
(Treatment Satisfaction Questionnaire for Medication a3). Subjects randomized (1:1,
blinded) to paliperidone ER 6 mg/day (optional increase to 12 mg/day) either imme-
diately (6 weeks total) or delayed (continued risperidone for 2 weeks followed by 
paliperidone ER for 4 weeks). Primary end point for the overall group: change in
Medication Satisfaction Questionnaire (MSQ) (1  extremely dissatisﬁ ed to 7 
extremely satisﬁ ed) at week 6 end point. Additional end points: total PANSS and 
adverse events (AEs). Study ID: CR014347. RESULTS: 201 subjects were randomized 
to immediate (n  100) or delayed (n  101) initiation of paliperidone ER. For the 
overall group, mean (SD) MSQ score improved signiﬁ cantly from 2.7 (0.8) at baseline
to 5.1 (1.2) at end point (P  0.001). 82.7% of subjects were satisﬁ ed with their
medication at end point vs 3.7% at baseline. Mean (SD) PANSS total score improved 
from baseline to end point (¨C12.9 [13.1]; P  0.001). At week 2, a higher percentage
of subjects receiving paliperidone ER (immediate-initiation group) were satisﬁ ed with 
their medication compared with those still receiving risperidone (delayed-initiation 
group) (67.7% vs 45.3%; P  0.002). Most common AEs for overall group: insomnia 
(9.1%), constipation (7.6%), headache (7.6%) and somnolence (6.6%). CONCLU-
SIONS: Schizophrenia subjects suboptimally responsive to risperidone reported
improved medication satisfaction after 4 or 6 weeks of paliperidone ER.
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OBJECTIVES: Pharmacist’s dissatisfaction with the work caused by inadequate job 
demands, working environments and administrative requirements might lead to poor
performance, personnel’s burnout and turnover rate. However, the issues have been
scantly acknowledged. This study aimed to investigate the job satisfaction among 
hospital pharmacists in Taiwan. METHODS: Semi-structured interviews were con-
ducted with nine hospital pharmacists to explore the main concerns regarding job
satisfaction of the hospital pharmacists. Subsquently content analysis was performed 
to produce a questionnaire with 24 items covering dispensing workload, salary, beneﬁ t 
packages, education, and training. After the reliability and validity of the questionnaire
were tested, the revised questionnaire was distributed to all pharmacists in a medical 
center in Taipei. RESULTS: In total, 66.36% of 110 pharmacists responded to the
survey. Satisfaction scores ranged from 5 (extremely satisﬁ ed) to 1 (extremely dissatis-
ﬁ ed). The participants in this study were most satisﬁ ed with the working relationships 
with colleagues, the leadership of the head of pharmacy department, and the compe-
tency for providing patient consultations. The participants were most dissatisﬁ ed with
the heavy workload, night shifts, and the promotion system. The total mean satisfac-
tion score was 3.17 / 0.74, slightly higher than the mean value, without signiﬁ cant 
difference among varied groups of age, gender, salary, education levels and working 
years. However, longer working years seemed to signiﬁ cantly relate to higher satisfac-
tion level in salary. (F  3.17, P  0.01). CONCLUSIONS: It is recommended that 
decision makers need to consider the salary and shift systems to improve job satisfac-
tion of the pharmacists. Further survey is planned to distribute this questionnaire to 
a larger groups of pharmacists working in different levels of medical settings.
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OUTCOMES ASSESSMENT OF AN ANTIPSYCHOTIC DRUG ALGORITHM: 
EFFECTS OF THE MISSISSIPPI STATE HOSPITAL ALGORITHM PROJECT
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1Mississippi State Hospital, Whitﬁ eld, MS, USA, 2Pﬁ zer, New York, NY, USA
OBJECTIVES: To evaluate use of an optional antipsychotic drug algorithm for treat-
ing inpatients with schizophrenia or schizoaffective disorder at a state psychiatric 
hospital. METHODS: Clinical outcomes were compared in patients whose treatment
followed a speciﬁ c antipsychotic drug algorithm versus those whose did not. First step
oral antipsychotic options in the algorithm were risperidone and ziprasidone. Docu-
mentation of a clinical rationale for use of a non-preferred drug was acceptable for
deviating from preferred choices. Antipsychotic polytherapy was the least preferred 
treatment. Steps for using injectable and non-preferred drugs were also speciﬁ ed.
Primary and secondary outcomes were length of hospitalization and patient achieve-
ment of “much improved” or “very much improved”, deﬁ ned by CGI-S score, respec-
tively. Prescribers reviewed patient record documentation to compare patients who
were adherent vs non-adherent to the algorithm. RESULTS: The total cohort was 401 
patients (263 algorithm adherent and 138 non-adherent). Three algorithm adherent 
patients were dropped due to a CGI-S score of 7 therefore, 260 were used in the 
analysis. Sixty-seven percent were male. The mean age was 39. The median number
of past hospitalizations was 2. The modal rating of severity on the Clinical Global 
Impression—Severity was 5, markedly ill. There were no signiﬁ cant differences 
between groups on gender, number of past hospitalizations and severity of illness. No 
signiﬁ cant between group differences were observed for mean length of stay (adherent
49 days, non-adherent 45 days), p  0.12, least squares means (adjusted for CGI-S,
gender and exacerbations) or time to improvement, p  0.31, log-rank test. CONCLU-
SIONS: Use of an optional algorithm for inpatients, designed to improve cost efﬁ ciency
without denying access to non-preferred medications, did not prolong length of stay 
or delay time to desired improvement.
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THE IMPACT OF THE FDA ANTIDEPRESSANT BLACK BOX WARNING
ON THE CONTINUITY OF ANTIDEPRESSANT TREATMENT IN
CHILDREN WITH DEPRESSION
Pawar DS, Saundankar V, Akinwunmi P, Tseng F, Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: To assess the impact of the FDA antidepressant Black Box warning on
treatment continuity of antidepressants in children with depression. METHODS: The 
study was a retrospective cohort analysis using 2003–2004 Texas Medicaid claims 
data obtained from Center for Medicare and Medicaid Services. Study cohort included 
patients who were 1) continuously enrolled for Texas Medicaid from January 2003 
to December 2004; 2) at age of 6 to 18; 3) receiving at least two outpatient diagnoses 
with depressive disorders (ICD9-CM codes: 296.xx, 293.xx, 298.xx, 300.xx, 301.xx, 
309.xx, 311.xx) and 4) using Selective Serotonin Re-uptake Inhibitors (SSRIs) pre-
scriptions. Initiation of SSRI therapy was deﬁ ned as ﬁ rst prescription ﬁ ll during
January 1, 2003-January 30, 2003 for the pre-policy cohort and January 1, 2004 – 
January 30, 2004 for the policy cohort. Both cohorts were followed till the end of the
year to observe treatment discontinuation. The discontinuation of SSRI treatment was
deﬁ ned as a gap of 30 days or more between prescriptions. Cox proportional hazard
model was applied to examine the risk of treatment discontinuity due to FDA public
advisory on antidepressants in March 2004. RESULTS: A total of 7184 children 
who met all inclusive criteria were identiﬁ ed, out of which 3367 were in pre-policy 
cohort and 3817 were in policy cohort. Mean age of cohort was 13.75 (SD  3.81). 
The average during pre-policy and policy period were 61.83 days and 55.65 days
respectively. After FDA issued the public advisory on antidepressant in March 2004, 
the risk of antidepressant discontinuation did not change (HR  1.148, 95% CI 
0.907–1.453, p-value  0.2945) compared to the pre-policy period after controlling
patient demographics. CONCLUSIONS: The FDA public advisory on antidepressants 
was not associated with increased risk of SSRI antidepressant treatment discontinua-
tion. Further study is warranted to assess the long term effects of the Black box 
warning on the use of antidepressants.
